GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have become one of the biggest stories in healthcare, obesity medicine, pharma, telehealth, and even culture.But are GLP-1s truly transforming obesity care — or are we outsourcing willpower to pharma?In this episode of Digital Health Inside Out, Alex Koshykov and Sergey Polevikov sit down with Dr. Beverly Chang, Dave Knapp, and Sean Sullivan to unpack the science, business, safety concerns, access issues, and social debate around GLP-1 medications.